Brainsway Ltd.

Foreign Filer Report • Nov 13, 2025

BrainsWay Receives FDA Clearance of Deep TMS� as Adjunct Therapy for MajorDepressive Disorder (MDD) in Adolescents Aged 15 to 21 false

���������� ��"�	2 380
BRAINSWAY LTD
Corporation no: 513890764	10767
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	12/11/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-086585	Time of broadcast: 15:42 15:42

---

The corporation scheduled the publication of the report to 13/11/2025 13:00Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBrainsWay Receives FDA Clearance of Deep TMS� as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21

BrainsWay_FDA_Clerance_for_Adolescent_MDD_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: BWAY	Date of revision of form structure: 06/08/2024
Address: ����� 19 , ������� 91451   , Tel: 02-5813140 , Fax: 02-5812517
E-mail address: uri@Brainsway.com   Company site: www.Brainsway.com
Previous names of reporting entity:
Name of the Signatory: Levy Hadar Position of Signatory in the reporting corporation: Chief Financial Officer Name of Employer Company:
Address: Hartum Street, Bynet Building 19 , Jerusalem 9777518 Telephone: 97225824030 Facsimile: 97225812517 E-mail: hadarl@brainsway.com 1